Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Pevion Biotech AG" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Pevion Biotech AG for you to read. Along with our medical data and news we also list Pevion Biotech AG Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pevion Biotech AG Companies for you to search.
Man, it makes me so nervous when small biotech companies take on debt. The term "non-dilutive" might sound nice but you have to pay it back and it gives you little room for something to go wrong.
The $68 million fund raise comes on top of $42 million that Karuna, a privately held 10-year-old firm, raised last year to develop its experimental medicine.
Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that it has secured a €20 million revolving credit facility with Natixis, the French Corporate and Investment bank. The credit facility will have ...
Novartis, Pfizer, Novo Nordisk: Die Biotech-Schmiede Amarin wurde zuletzt mit einigen großen Pharma-Konzernen als Übernahmekandidat in Verbindung gebracht. Hauptursache für die Gerüchte ist Vascepa...
USDM and Oracle are evolving GxP compliance in the cloud. SANTA BARBARA, Calif. (PRWEB) March 18, 2019 For more than 15 years, USDM Life Sciences and Oracle have partnered together to develop solutions that allow life science companies to easily comply with FDA 21 CFR Part 11 and EMA EudraLex Volume 4 Annex 11 regulatory requirements. USDM’s Cloud Assurance™ is a managed service delivering en...
Edison Investment Research Limited 18-March-2019 / 12:33 GMT/BST London, UK, 18 March 2019 Edison initiates coverage on Actinogen Medical (ACW) Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem(R) is a selective 11β-HSD1 inhibitor that is able to cross the bloo...
STAT Plus: Regeneron's Dupixent is a commercial blockbuster. Now the small biotech Dermira could challenge that dominance in eczema treatment. https://buff.ly/2UIFLYH
Unique Delivery System Ensures Quality Product COLUMBUS, Ohio and BERKELEY, Calif. (PRWEB) March 18, 2019 3Bar Biologics, the cutting-edge biotech company and Pivot Bio, the leader in microbial solutions announce today they have entered into an agreement for 3Bar to provide a proprietary delivery system for Pivot Bio PROVENTM, Pivot Bio’s breakthrough product for biologic nitrogen fixation for ...
Arix Biosciences claims a 10% stake in the biotech
UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest birch allergy product failed to reduce symptoms. The biotech already markets jabs for tree pollen, dust mites, and grass pollen and is exp...
UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed its primary endpoint in the treatment of birch-pollen induced seasonal allergic rhinitis. Newly revealed Phase 3 data indicated that the drug “did not show a statistically significant difference between active and placebo arms”, with trial participant...
BREAKING: A Regeneron drug dominates eczema treatment. With new data, a small biotech believes it can compete https://buff.ly/2Fazy1e
Regeneron's Dupixent is a commercial blockbuster. Now the small biotech Dermira could challenge that dominance in eczema treatment.
US biotech Imara has raised $63 million for clinical development of its sickle cell disease drug, which is in mid-stage development. Imara attracted investors including Arix Bioscience, which has invested $15 million for a 10% stake, and will also...
The dermatology-focused biotech is now mulling a late-stage trial that would test two higher-dose regimens of its drug, lebrikizumab.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...
Edison Investment Research - Pharmaceuticals & healthcare - Actinogen Medical: Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment ...
C $1,100.00End Date: Saturday Apr-6-2019 9:25:50 EDTBuy It Now for only: C $1,100.00Buy It Now | Add to watch list Biotech365 : VWR Sheldon Model 2005 Low Temperature Incubator Laboratory BioMarketplace You want to propose your products or a Biotech … Continue reading →
C $26.67 (0 Bids)End Date: Wednesday Mar-20-2019 14:47:14 EDTBid now | Add to watch list Biotech365 : VWR Stirrer Hotplate VMS-C7 S1-DG BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool or a Bioinformatic software … Continue reading →
50,00 EUR (0 Pujas)Fecha de finalización: domingo mar-24-2019 15:07:41 CETPujar ahora | Añadir a lista de seguimiento Biotech365 : Veco Thermistor 32A503 for RF power measurement like HP Agilent 432 BioMarketplace You want to propose your products or a Biotech … Continue reading →
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2018. L...
$850.00End Date: Sunday Apr-14-2019 15:33:38 PDTBuy It Now for only: $850.00Buy It Now | Add to watch list Biotech365 : AFFYMETRIX AGILENT GENE ARRAY SCANNER MODEL G2500A BioMarketplace You want to propose your products or a Biotech Company, a Biotech … Continue reading →
Soleno Therapeutics, Atossa Genetics, Agile Therapeutics, Syros Pharmaceuticals and Conatus Pharmaceuticals were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index Back in the Green appeared first on Investing News Network.
Edison Investment Research - Pharmaceuticals & healthcare - Actinogen Medical: Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem® is a selective 11β-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been assoc...
11,72 EUR (2 Pujas)Fecha de finalización: domingo mar-17-2019 19:00:56 CETPujar ahora | Añadir a lista de seguimiento Biotech365 : Leitz Wetzlar Microscope x40 Objective Lens NPL Fluotar 160/0.17 40/0.70 BioMarketplace You want to propose your products or a Biotech Company, … Continue reading →